Comparative Efficacy of Modified FOLFIRINOX and Gemcitabine plus Nab-paclitaxel in Pancreatic CancerComparing Two Main Chemotherapy Options for Patients with Pancreatic Cancer

Frontiers in Medicine Published September 28, 2026 DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Gemcitabine plus nab-paclitaxel demonstrates superior OS and PFS compared to modified FOLFIRINOX in unresectable cases.

This systematic review and meta-analysis evaluated the clinical outcomes of modified FOLFIRINOX (mFFX) versus gemcitabine plus nab-paclitaxel (GnP) in patients with unresectable pancreatic cancer. The analysis focused on primary endpoints of overall survival (OS) and progression-free survival (PFS) across a large cohort of 1,204 patients.

Statistical analysis demonstrated that patients receiving mFFX experienced significantly shorter OS (HR 1.26, P=0.002) and shorter PFS (HR 1.21, P=0.01) compared to the GnP regimen. While the objective response rate showed no significant difference between the two treatments, the disease control rate was borderline lower for the mFFX group.

Safety profiles varied significantly between the two regimens. The mFFX group showed a much higher incidence of grade 3 or higher diarrhea and anorexia. Conversely, the GnP group was associated with more frequent instances of grade 3 neutropenia and white blood cell decreases. Clinicians should weigh these distinct toxicity profiles alongside patient performance status when selecting a first-line therapy.

How this fits prior evidence

This meta-analysis addresses a gap in comparing specific chemotherapy regimens for unresectable pancreatic cancer. It provides a direct comparison between mFFX and GnP, which differs from the finding that NALIRIFOx shows no significant difference in overall survival compared to FOLFIRINOX in pancreatic cancer. While the study identifies a survival advantage for GnP over mFFX, it does not provide data on the CALLY index or the cost-effectiveness of neoadjuvant regimens.

Doctors often have to choose between two main types of chemotherapy for patients with advanced pancreatic cancer. This study looked at many patients to see which treatment helped people live longer and stay healthy for a greater amount of time.

The study compared a modified FOLFIRINOX plan against a combination of gemcitabine and nab-paclitaxel. The results showed that the gemcitabine and nab-paclitaxel group had better overall survival. Patients on this specific treatment lived longer than those on the other option.

In addition to living longer, patients on the gemcitabine and nab-paclitaxel treatment had a better chance of keeping their cancer from growing for a longer period. While both treatments helped some patients shrink their tumors, the second option was more effective at controlling the disease.

Safety is also a major factor in choosing a treatment. The first option caused more severe stomach issues and loss of appetite. The second option was more likely to cause a drop in white blood cells. Doctors should look at a patient's age and overall health to pick the best path forward.

What this means for you:

Patients receiving gemcitabine and nab-paclitaxel lived longer and had better disease control than those on modified FOLFIRINOX.

Common questions

How do these two treatments compare for survival?

The study of 1,204 patients found that the gemcitabine and nab-paclitaxel combination was associated with longer overall survival and longer progression-free survival compared to modified FOLFIRINOX. This means patients on the gemcitabine and nab-paclitaxel treatment stayed stable for a longer period of time.

What are the side effects of these treatments?

Modified FOLFIRINOX was linked to a higher risk of severe diarrhea and loss of appetite. The gemcitabine and nab-paclitaxel combination was associated with more frequent drops in white blood cell counts. You should talk to your doctor about which side effects are most manageable for your specific health needs.

Is one treatment better for shrinking the tumor?

The study found no significant difference between modified FOLFIRINOX and the gemcitabine and nab-paclitaxel combination when it came to the objective response rate, which measures how much the tumor shrinks. However, the gemcitabine and nab-paclitaxel combination showed better results for overall survival.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedSep 2026

View Original Abstract ↓

ObjectiveModified FOLFIRINOX (mFFX) and gemcitabine plus nab-paclitaxel (GnP) are both recommended as standard first-line regimens for unresectable pancreatic cancer (PC). However, direct head-to-head comparative evidence remains scarce, and prior studies have largely failed to distinguish mFFX from standard FOLFIRINOX (sFFX). We systematically compared mFFX with GnP to evaluate their efficacy and toxicities.MethodsWe searched for randomized controlled trials (RCTs) and observational studies comparing mFFX with GnP as first-line therapy for unresectable PC published between January 2013 and May 2026. Overall survival (OS) and progression-free survival (PFS) were assessed using hazard ratios (HRs). Objective response rate (ORR) and disease control rate (DCR) were evaluated using risk ratios (RRs). Events of toxicities were assessed using odds ratios (ORs).ResultsFive studies (three RCTs and two retrospective studies) involving 1204 patients (578 in the mFFX arm and 626 in the GnP arm) were included. Compared with GnP, mFFX was associated with a shorter OS (HR 1.26, 95% CI 1.09–1.45; P = 0.002) and PFS (HR 1.21, 95% CI 1.04–1.40; P = 0.01), along with a borderline lower DCR (RR 0.90, 95% CI 0.81–1.00; P = 0.05; I2 = 62%), which was consistent across RCTs (RR 0.88, 95% CI 0.81–0.94; I2 = 0%) but not observed in retrospective studies (RR 0.96, 95% CI 0.71–1.29; I2 = 87%), and ORR did not differ significantly between the two regimens. As for toxicity profiles, mFFX showed an elevated incidence of grade ≥3 diarrhea (OR 5.63) and anorexia (OR 4.44). By contrast, grade ≥3 neutropenia (OR 0.66) and white blood cell decrease (OR 0.49) occurred more frequently under GnP.ConclusionsGnP was associated with more favorable OS and PFS than mFFX, a borderline DCR advantage, and distinct toxicity profiles. Given the modest effect size and the limitations of this study, clinical decision-making should integrate patient age, performance status, and anticipated second-line therapy.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251175959.

Comparative Efficacy of Modified FOLFIRINOX and Gemcitabine plus Nab-paclitaxel in Pancreatic CancerComparing Two Main Chemotherapy Options for Patients with Pancreatic Cancer

How this fits prior evidence

Common questions

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Comparative Efficacy of Modified FOLFIRINOX and Gemcitabine plus Nab-paclitaxel in Pancreatic CancerComparing Two Main Chemotherapy Options for Patients with Pancreatic Cancer

How this fits prior evidence

Common questions

More on Pancreatic Cancer

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Related in Oncology

From Other Specialties